Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients
Paassen, Pieter Van; Pittrow, David; Scheidegger, Clemens; Klotsche, Jens; Ellerbroek, Pauline M.
(2020) Immunotherapy, volume 12, issue 2, pp. 131 - 139
(Article)
Abstract
Aim: Data on the real-world use of hyaluronidase-facilitated subcutaneous 10% immunoglobulin (fSCIG; HyQvia®) in elderly patients with primary or secondary immunodeficiencies (PID or SID) are unreported. This study determined real-world patterns from one administration of fSCIG. Materials & methods: In this retrospective, multicenter study, medical records of patients aged ≥65
... read more
years with PID or SID were reviewed. Results: The majority of patients (mean age: 69.9 years) with PID (n = 10) or SID (n = 6) self-administered fSCIG (200-350 ml) at home every 3-4 weeks using a single infusion site by infusion pump at rates up to 300 ml/h. Conclusion: This study provides initial real-world evidence supporting home-based, self-administration of large volumes of fSCIG in elderly patients with PID or SID.
show less
Download/Full Text
Keywords: elderly patients, fSCIG, home infusion, HyQvia, primary immunodeficiencies, real-world study, recombinant human hyaluronidase-facilitated subcutaneous 10% immunoglobulin, secondary immunodeficiencies, Immunology and Allergy, Immunology, Oncology
ISSN: 1750-743X
Publisher: Taylor and Francis Ltd.
Note: Funding Information: V Ruvini Jayasinghe of Oxford PharmaGenesis Inc., Newtown, PA, USA provided editorial assistance, which was funded by Shire Funding Information: This study was funded by Baxalta Innovations GmbH, Vienna, Austria, a member of the Takeda group of companies. P van Paassen received a study grant from Shire, a member of the Takeda group of companies. D Pittrow reports personal fees from Actelion, Bayer, Aspen, Boehringer Ingelheim, Sanofi, Biogen and MSD, outside the submitted work. He has acted as consultant for Baxalta Innovations GmbH, a member of the Takeda group of companies. C Scheidegger has been an investigator of studies funded by Shire, Takeda or Baxalta. J Klotsche reported no conflicts of interest. PM Ellerbroek is a local investigator of studies funded by the Takeda group of companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2020 PM Ellerbroek.
(Peer reviewed)
